Enhanced Washout of 99mTc-tetrofosmin in Hypertrophic Cardiomyopathy: Quantitative Comparisons with Regional 123I-BMIPP Uptake and Wall Thickness Determined by MRI

Overview

Journal Eur J Nucl Med Mol Imaging

Specialties Biophysics
Nuclear Medicine
Radiology

Date 2003 May 21

PMID 12756503

Citations 3

Authors

Thet-Thet-Lwin

Tohoru Takeda

Jin Wu

Yuko Fumikura

Keiji Iida

Satoru Kawano

Iwao Yamaguchi

Yuji Itai

Affiliations

Soon will be listed here.

Abstract

The diagnostic value of technetium-99m tetrofosmin (TF) washout in hypertrophic cardiomyopathy (HCM) was examined by investigating its relation to the metabolic abnormality depicted by iodine-123 beta-methyl- p-iodophenylpentadecanoic acid (BMIPP) uptake and the left ventricular (LV) myocardial wall thickness as measured by magnetic resonance imaging (MRI). TF washout was evaluated in 31 patients with HCM and 23 normal control subjects using 30-min (early) and 3-h (delayed) TF single-photon emission tomography images. The LV myocardial wall was divided into 19 segments and the percentage TF washout, regional BMIPP uptake and LV wall thickness were measured in each segment. Mean TF washout in the patients with HCM was significantly faster than that in normal control subjects (23.7+/-5.7 vs 13.4+/-4.1, P<0.0001). In the patients with HCM, TF washout showed an excellent correlation with MRI wall thickness ( r=0.82, P<0.0001) and a good inverse correlation with regional BMIPP uptake ( r=-0.72, P<0.0001). In addition, a good linear correlation was observed between TF uptake and MRI wall thickness in the 19 regional segments. In conclusion, the degree of TF washout corresponds well with the severity of myocardial wall thickness and the degree of metabolic abnormality in patients with HCM. These results suggest that enhanced TF washout might provide additional clinical information regarding metabolic alterations in HCM.

Citing Articles

Clinical Implications of the Washout Phenomenon in Technetium-99m (Tc-) Labeled Compounds for Myocardial Perfusion Imaging.

Taniguchi Y Ann Nucl Cardiol. 2024; 10(1):55-58.

PMID: 39635330 PMC: 11612402. DOI: 10.17996/anc.24-00010.

Relation of 99mTc-sestamibi washout with myocardial properties in patients with hypertrophic cardiomyopathy.

Isobe S, Ohshima S, Unno K, Izawa H, Kato K, Noda A J Nucl Cardiol. 2010; 17(6):1082-90.

PMID: 20635229 DOI: 10.1007/s12350-010-9266-7.

Evolving anatomic, functional, and molecular imaging in the early detection and prognosis of hypertrophic cardiomyopathy.

Fuster V, van der Zee S, Miller M J Cardiovasc Transl Res. 2010; 2(4):398-406.

PMID: 20559998 DOI: 10.1007/s12265-009-9133-6.

References

Kurata C, Tawarahara K, Taguchi T, Aoshima S, Kobayashi A, Yamazaki N . Myocardial emission computed tomography with iodine-123-labeled beta-methyl-branched fatty acid in patients with hypertrophic cardiomyopathy. J Nucl Med. 1992; 33(1):6-13. View

Sochor H, Schelbert H, Schwaiger M, Henze E, Phelps M . Studies of fatty acid metabolism with positron emission tomography in patients with cardiomyopathy. Eur J Nucl Med. 1986; 12 Suppl:S66-9. DOI: 10.1007/BF00258110. View

Arbab A, Koizumi K, Toyama K, Arai T, Araki T . Technetium-99m-tetrofosmin, technetium-99m-MIBI and thallium-201 uptake in rat myocardial cells. J Nucl Med. 1998; 39(2):266-71. View

Grover-McKay M, Schwaiger M, Krivokapich J, PERLOFF J, Phelps M, Schelbert H . Regional myocardial blood flow and metabolism at rest in mildly symptomatic patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 1989; 13(2):317-24. DOI: 10.1016/0735-1097(89)90505-6. View

Takeishi Y, Chiba J, Abe S, Tonooka I, Komatani A, Tomoike H . Heterogeneous myocardial distribution of iodine-123 15-(p-iodophenyl)-3-R,S-methylpentadecanoic acid (BMIPP) in patients with hypertrophic cardiomyopathy. Eur J Nucl Med. 1992; 19(9):775-82. DOI: 10.1007/BF00182819. View

Tanaka R, Nakamura T . Time course evaluation of myocardial perfusion after reperfusion therapy by 99mTc-tetrofosmin SPECT in patients with acute myocardial infarction. J Nucl Med. 2001; 42(9):1351-8. View

Fujibayashi Y, Yonekura Y, Takemura Y, Wada K, Matsumoto K, Tamaki N . Myocardial accumulation of iodinated beta-methyl-branched fatty acid analogue, iodine-125-15-(p-iodophenyl)-3-(R,S)methylpentadecanoic acid (BMIPP), in relation to ATP concentration. J Nucl Med. 1990; 31(11):1818-22. View

Shimizu M, YOSHIO H, Ino H, Taki J, Nakajima K, Bunko H . Myocardial scintigraphic study with 123I 15-(p-iodophenyl)-3(R,S)-methylpentadecanoic acid in patients with hypertrophic cardiomyopathy. Int J Cardiol. 1996; 54(1):51-9. DOI: 10.1016/0167-5273(95)02536-7. View

Arbab A, Koizumi K, Toyama K, Araki T . Uptake of technetium-99m-tetrofosmin, technetium-99m-MIBI and thallium-201 in tumor cell lines. J Nucl Med. 1996; 37(9):1551-6. View

10.

Fujiwara S, Takeishi Y, Atsumi H, Takahashi K, Tomoike H . Fatty acid metabolic imaging with iodine-123-BMIPP for the diagnosis of coronary artery disease. J Nucl Med. 1997; 38(2):175-80. View

11.

Younes A, Songadele J, Maublant J, Platts E, Pickett R, Veyre A . Mechanism of uptake of technetium-tetrofosmin. II: Uptake into isolated adult rat heart mitochondria. J Nucl Cardiol. 1995; 2(4):327-33. DOI: 10.1016/s1071-3581(05)80077-7. View

12.

Rigo P, Leclercq B, Itti R, Lahiri A, Braat S . Technetium-99m-tetrofosmin myocardial imaging: a comparison with thallium-201 and angiography. J Nucl Med. 1994; 35(4):587-93. View

13.

Kagaya Y, Ishide N, Takeyama D, Kanno Y, Yamane Y, Shirato K . Differences in myocardial fluoro-18 2-deoxyglucose uptake in young versus older patients with hypertrophic cardiomyopathy. Am J Cardiol. 1992; 69(3):242-6. DOI: 10.1016/0002-9149(92)91313-s. View

14.

Sugihara H, Kinoshita N, Adachi Y, Taniguchi Y, Ohtsuki K, Azuma A . Early and delayed Tc-99m-tetrofosmin myocardial SPECT in patients with left bundle branch block. Ann Nucl Med. 1998; 12(5):281-6. DOI: 10.1007/BF03164914. View

15.

Henry W, Clark C, Epstein S . Asymmetric septal hypertrophy. Echocardiographic identification of the pathognomonic anatomic abnormality of IHSS. Circulation. 1973; 47(2):225-33. DOI: 10.1161/01.cir.47.2.225. View

16.

Kjaer A, Cortsen A, Rahbek B, Hasseldam H, Hesse B . Attenuation and scatter correction in myocardial SPET: improved diagnostic accuracy in patients with suspected coronary artery disease. Eur J Nucl Med Mol Imaging. 2002; 29(11):1438-42. DOI: 10.1007/s00259-002-0932-0. View

17.

Morishita S, Kondo Y, Nomura M, Miyajima H, Nada T, Ito S . Impaired retention of technetium-99m tetrofosmin in hypertrophic cardiomyopathy. Am J Cardiol. 2001; 87(6):743-7. DOI: 10.1016/s0002-9149(00)01494-6. View

18.

Unverferth D, BAKER P, Pearce L, Lautman J, Roberts W . Regional myocyte hypertrophy and increased interstitial myocardial fibrosis in hypertrophic cardiomyopathy. Am J Cardiol. 1987; 59(9):932-6. DOI: 10.1016/0002-9149(87)91128-3. View

19.

Sugihara H, Adachi Y, Nakamura T, Ohtsuki K, Okuyama C, Ushijima Y . Long-term follow-up of myocardial perfusion and metabolic images in a patient with hypertrophic cardiomyopathy. Clin Nucl Med. 2000; 25(3):206-7. DOI: 10.1097/00003072-200003000-00011. View

20.

Maron B . Asymmetry in hypertrophic cardiomyopathy: the septal to free wall thickness ratio revisited. Am J Cardiol. 1985; 55(6):835-8. DOI: 10.1016/0002-9149(85)90166-3. View